The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway ...
Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...
The Institute of Cancer Research, London, strongly welcomes the news that the targeted drug capivasertib, has been approved by the US Food and Drug Administration (FDA) for treating a type of advanced ...
AstraZeneca’s TRUQAP ® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...
The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...
The first-in-class AKT inhibitor combination significantly reduced the risk of radiographic disease progression or death by 19% in an aggressive prostate cancer subtype. The Food and Drug ...
TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris ...
Pharmaceutical Technology on MSN
FDA oncology roundup: drugs, imaging agents and diagnostics gain approval
The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.
Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Based on results of CAPItello-281 which prospectively defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results